NJ State Employees Deferred Compensation Plan’s AstraZeneca AZN Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,559	Closed	-$1.47M	–	42
2025 Q3	$1.47M	Hold	9,559	–	–	0.16%	137
2025 Q2	$1.34M	Hold	9,559	–	–	0.16%	142
2025 Q1	$1.41M	Hold	9,559	–	–	0.18%	135
2024 Q4	$1.25M	Hold	9,559	–	–	0.15%	154
2024 Q3	$1.49M	Hold	9,559	–	–	0.18%	133
2024 Q2	$1.49M	Hold	9,559	–	–	0.19%	116
2024 Q1	$1.3M	Hold	9,559	–	–	0.16%	138
2023 Q4	$1.29M	Hold	9,559	–	–	0.18%	127
2023 Q3	$1.29M	Hold	9,559	–	–	0.2%	121
2023 Q2	$1.37M	Hold	9,559	–	–	0.2%	118
2023 Q1	$1.33M	Hold	9,559	–	–	0.2%	117
2022 Q4	$1.3M	Hold	9,559	–	–	0.21%	120
2022 Q3	$1.05M	Hold	9,559	–	–	0.18%	139
2022 Q2	$1.26M	Hold	9,559	–	–	0.21%	116
2022 Q1	$1.27M	Sell	9,559 -1	-0%	-$120	0.17%	138
2021 Q4	$1.11M	Hold	9,560	–	–	0.14%	166
2021 Q3	$1.15M	Buy	+9,560	New	+$1.11M	0.16%	140

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's AZN Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 9,559 shares — an estimated $1.47M sold.

NJ State Employees Deferred Compensation Plan first reported a position in AZN in Q3 2021 and held it in 17 quarters. The position peaked at $1.49M in Q2 2024. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 9,559 AstraZeneca shares in Q4 2025, an estimated $1.47M.
NJ State Employees Deferred Compensation Plan first reported a position in AstraZeneca in Q3 2021 and held it in 17 quarters.
NJ State Employees Deferred Compensation Plan's AstraZeneca position peaked at $1.49M in Q2 2024.
1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.